NCT02928393 is a Phase 2 clinical trial of Basmisanil in Stroke, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT02928393?

NCT02928393 is sponsored by Hoffmann-La Roche.

What drugs are being tested in NCT02928393?

Interventions in NCT02928393: Basmisanil, Placebo.

Is NCT02928393 still recruiting?

NCT02928393 is currently terminated. Last updated 2 January 2019.

Last reviewed 2019-01-02 · How we verify

NCT02928393

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke

Terminated Phase 2 Last updated 2 January 2019

What this trial tests

Phase 2 trial testing Basmisanil in Stroke in 5 participants. Terminated before completion.

Timeline

20 February 2017

Primary endpoint
3 November 2017

3 November 2017

Quick facts

Lead sponsor	Hoffmann-La Roche
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	5
Start date	20 February 2017
Primary completion	3 November 2017
Estimated completion	3 November 2017
Sites	13 locations across France, Spain

Drugs / interventions tested

Basmisanil — full drug profile →
Placebo

Conditions studied

Stroke — all drugs for Stroke →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

Adults 40 to 85, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase IIa, randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety, efficacy and pharmacodynamics of basmisanil in adult participants with severe motor impairment following an ischemic stroke.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Encouraging an excitable brain state: mechanisms of brain repair in stroke.
Joy MT, Carmichael ST. · · 2021 · cited 208× · PMID 33184469 · DOI 10.1038/s41583-020-00396-7
New Directions in Treatments Targeting Stroke Recovery.
Lin DJ, Finklestein SP, Cramer SC. · · 2018 · cited 69× · PMID 30571435 · DOI 10.1161/strokeaha.118.021359
Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man.
Hipp JF, Knoflach F, Comley R, Ballard TM, et al · · 2021 · cited 27× · PMID 33833333 · DOI 10.1038/s41598-021-87307-7
The Delta-Subunit Selective GABA A Receptor Modulator, DS2, Improves Stroke Recovery via an Anti-inflammatory Mechanism.
Neumann S, Boothman-Burrell L, Gowing EK, Jacobsen TA, et al · · 2019 · cited 20× · PMID 31736685 · DOI 10.3389/fnins.2019.01133
The Gliopeptide ODN, a Ligand for the Benzodiazepine Site of GABAA Receptors, Boosts Functional Recovery after Stroke.
Lamtahri R, Hazime M, Gowing EK, Nagaraja RY, et al · · 2021 · cited 16× · PMID 34210784 · DOI 10.1523/jneurosci.2255-20.2021
Long-term α5 GABA A receptor negative allosteric modulator treatment reduces NMDAR-mediated neuronal excitation and maintains basal neuronal inhibition.
Nuwer JL, Povysheva N, Jacob TC. · · 2023 · cited 6× · PMID 37270156 · DOI 10.1016/j.neuropharm.2023.109587

Verify or expand the search:

Other trials of Basmisanil

Trials testing the same drug.

NCT05307679 — A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome · Phase 2 · terminated
NCT02953639 — A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (C · Phase 2 · completed

Other recruiting trials for Stroke

Currently open trials in the same condition.

NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
NCT07356011 — Exoskeleton for Balance · NA · recruiting
NCT07523503 — Unilateral Versus Bilateral Task-specific Training on Motor Impairment, Upper Extremity Function, and Hand Dexterity in · NA · recruiting
NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02928393 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 2 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02928393.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing